10x Insights
Loading account…
Companies / Industrials / OptimizeRx Corp
OPRX

OptimizeRx Corp

IndustrialsBusiness Services
Ticker OPRXWALTHAM, MAFiscal year ends DecemberBook value per share $6.98Diluted shares 18.8M

OptimizeRx Corporation (OPRX) operates a digital health platform that connects pharmaceutical manufacturers, healthcare providers, and patients through targeted digital communications and data analytics. The company's website is www.optimizerx.com. From the company’s description.

Fiscal year 2025 · ends 12-31Changes are against fiscal 2024The amber dot is the latest twelve months, to 2026-06-30
Sales & profitability
$109.43M
+18.8% year over year
Last 12 mo $98.65M
10.69%
+25.6 percentage points
Last 12 mo 11.08%
$5.13M
+125.5% year over year
Last 12 mo $4.60M
4.21%
+15.1 percentage points
Last 12 mo 3.51%
Cash & financing
$18.71M
+282.8% year over year
Last 12 mo $18.43M
$18.66M
+320.3% year over year
Last 12 mo $18.42M
0.20
Was 0.28× a year earlier
Last 12 mo 0.15
19.0M
+3.9% year over year
Last 12 mo 18.8M

Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.

What OptimizeRx Corp does

In the company’s own words

OptimizeRx Corporation (OPRX) operates a digital health platform that connects pharmaceutical manufacturers, healthcare providers, and patients through targeted digital communications and data analytics. The company's website is www.optimizerx.com.

The company operates primarily through its core digital health communications business, which leverages proprietary algorithms and data analytics to identify trends and enable personalized digital outreach to patients and healthcare providers. OptimizeRx's platform facilitates connections between pharmaceutical companies seeking to promote their products and patients who may benefit from those medications, while also providing healthcare providers with relevant clinical information and patient support resources.

The business model centers on channel partnerships and data provider relationships that enable digital connectivity to patients and doctors. These partnerships provide OptimizeRx with access to communication channels and data insights necessary to deliver targeted, relevant messaging at scale. The company's revenue is generated primarily through fees paid by pharmaceutical manufacturers for access to the platform and the ability to reach specific patient and provider audiences.

OptimizeRx's competitive advantages include its proprietary algorithms for identifying patient populations, its established relationships with channel partners and data providers, and its integrated platform that streamlines the process of connecting pharmaceutical companies with their target audiences. The company operates in the digital health and pharmaceutical marketing technology sector, which has experienced significant growth as pharmaceutical companies increasingly shift marketing budgets toward digital channels and data-driven targeting.

The company expanded its capabilities through the acquisition of Healthy Offers, Inc., which was consummated on the closing date of the financing agreement referenced in this document. This acquisition, funded through a $40 million term loan facility provided by Blue Torch Finance, LLC and related lenders, represents a strategic expansion of OptimizeRx's digital health platform and service offerings to pharmaceutical manufacturers and healthcare stakeholders.

Company details
Sector
Industrials
Industry
Business Services
Headquarters
WALTHAM, MA
Fiscal year end
December
CIK
1448431
SIC
7389

Financial performance, year by year

Fiscal 2013–2025 · USD
$-33.06M$5.80M$44.66M$83.52M$122.38M2013201420152016201720182019202020212022202320242025Last 12 moLast 12 monthsLast 12 months

The full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.

Ownership

Who owns OptimizeRx Corp — and what changed

Funds as of 2026Q2 · superinvestors as of 2026-06-30

88
funds hold it
0 of 35
superinvestors hold it
$20.19M
held by funds, at market
18.6%
of shares held by funds

Largest fund holders · OptimizeRx Corp’s weight in each

0.21%of fund net assets
VANGUARD TOTAL STOCK MARKET INDEX FUND
VTI · VANGUARD INDEX FUNDS
0.00%of fund net assets
Jacob Internet Fund
JAMFX · Jacob Funds Inc.
3.61%of fund net assets
VANGUARD EXTENDED MARKET INDEX FUND
VXF · VANGUARD INDEX FUNDS
0.00%of fund net assets
Invenomic Fund
BIVIX · NORTHERN LIGHTS FUND TRUST II
0.11%of fund net assets

Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.

Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.

Could not be determined for this company: bond issues.

Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.

Connected research

Put this business in context.

Compare this company with peers, find it in your funds and follow its financial history with your connected AI:

  • “How do OptimizeRx Corp and its peers compare on margins and cash generation over ten years?”
  • “Where did five years of OptimizeRx Corp's earnings go — cash, debt, buybacks, reinvestment?”
  • “What changed in OptimizeRx Corp's last four quarterly filings that the numbers alone won't show?”
See how it works →All research tools with a subscription. Use your own AI account.